These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8766107)

  • 1. [Effect of estradiol valerate and chlormadinone acetate in hormone replacement therapy in postmenopause on Kupperman index, body weight, blood pressure, lipids, enzymes and electrolytes].
    Göretzlehner G; Nikschick S; Zimmermann T
    Zentralbl Gynakol; 1996; 118(7):420-5. PubMed ID: 8766107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the combined hormonal replacement drug estradiol valerate/levonorgestrel on climacteric complaints, endometrium and lipid profile of peri- and postmenopausal women.
    Georgiev DB; Golbs S; Goudev A
    Methods Find Exp Clin Pharmacol; 2001 May; 23(4):197-202. PubMed ID: 11676228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous hormone replacement therapy with estradiol valerate and chlormadinone acetate in adjustable dosages. A preliminary study.
    Rauch U; Taubert HD
    Maturitas; 1993 Sep; 17(2):123-7. PubMed ID: 7694047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect and tolerability of sequential administration of estradiol valerate and medroxyprogesterone acetate on menopausal symptoms, hormonal profile and biochemical markers in climacteric women].
    Radowicki S; Skórzewska K; Borakowska B; Wierzba W; Michalewski K
    Ginekol Pol; 2004 Jan; 75(1):39-46. PubMed ID: 15112472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3.
    Tuppurainen M; Heikkinen AM; Penttilä I; Saarikoski S
    Maturitas; 1995 Jun; 22(1):55-61. PubMed ID: 7666817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Estradiol valerate/cyproterone acetate in the treatment of climacteric syndrome].
    Zivný J; Skrenková J
    Ceska Gynekol; 1996 Oct; 61(5):294-6. PubMed ID: 9004975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Blood lipids and the clinical state of hormone-treated women during menopause].
    Dominiczak-Gawrońska M
    Ann Acad Med Stetin; 1989; 35():145-66. PubMed ID: 2484147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term sequential treatment with combined estradiol valerate and cyproterone acetate in early postmenopause.
    Polatti F; Capuzzo E; Viazzo F; Colleoni R; Abbiati I; Nappi RE
    Acta Obstet Gynecol Scand; 1999 Jan; 78(1):49-53. PubMed ID: 9926892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estradiol valerate/dienogest.
    Wellington K; Perry CM
    Drugs; 2002; 62(3):491-504; discussion 505-6. PubMed ID: 11827562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of the hormone replacement drug estradiol valerate/levonorgestrel in the treatment of menopausal syndrome in Thai women.
    Chittacharoen A; Domhardt R; Manonai J; Golbs S
    Methods Find Exp Clin Pharmacol; 2003 Oct; 25(8):645-51. PubMed ID: 14671683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum lipids in treatment with transdermal estradiol and oral norethisterone acetate].
    Mück AO; Salbach B; Rabe T; von Holst T; Runnebaum B
    Geburtshilfe Frauenheilkd; 1995 Jul; 55(7):393-9. PubMed ID: 7557206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormone replacement therapy with 17 beta-estradiol dydrogesterone: results of a 3-month open-label study].
    Grisar J; Travica S; Metka M; Pietschmann P
    Wien Klin Wochenschr; 1999 Dec; 111(24):1035-43. PubMed ID: 10677891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
    Marslew U; Overgaard K; Riis BJ; Christiansen C
    Obstet Gynecol; 1992 Feb; 79(2):202-10. PubMed ID: 1309944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of a sequential combination of estradiol valerate and cyproterone acetate on the functional properties of the arterial wall in menopausal women].
    Mares P; Dauzat M; Abramovici Y; Deklunder G; Body G; Crepin G; Denis A; Favier M
    Gynecol Obstet Fertil; 2000; 28(7-8):509-17. PubMed ID: 10996962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate.
    Imthurn B; Rosselli M; Jaeger AW; Keller PJ; Dubey RK
    J Clin Endocrinol Metab; 1997 Feb; 82(2):388-94. PubMed ID: 9024224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in serum lipids during treatment with norgestrel, oestradiol-valerate and cycloprogynon.
    Nielsen FH; Honoré E; Kristoffersen K; Secher NJ; Pedersen GT
    Acta Obstet Gynecol Scand; 1977; 56(4):367-70. PubMed ID: 602705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate.
    Castelo-Branco C; Casals E; Sanllehy C; Duran M; Fortuny A; Vanrell JA
    J Reprod Med; 1996 Nov; 41(11):833-8. PubMed ID: 8951134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl estradiol.
    Grandi G; Piacenti I; Volpe A; Cagnacci A
    Gynecol Endocrinol; 2014 Sep; 30(9):676-80. PubMed ID: 24918262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of antiandrogens in hormone replacement therapy.
    Schneider HP
    Climacteric; 2000 Dec; 3 Suppl 2():21-7. PubMed ID: 11379383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.